- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02205996
The Effects of Hypoglycaemia in People With Type 2 Diabetes
The Effects of Hypoglycaemia on Platelets Function and Inflammatory Markers in People With Type 2 Diabetes and Normal Controls.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Type 2 diabetes is associated with increased risk of cardiovascular disease. Although the United Kingdom Prospective Diabetes Study (UKPDS) follow-up data suggested reduced macrovascular complications with tight glycaemic control, recent studies in people with type 2 diabetes failed to replicate these findings. Furthermore, all-cause mortality was found to be increased with strict glycaemic control in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. The cause of the increased deaths remains unclear.
Strict glycaemic control is associated with increased risk of hypoglycaemia. Although, hypoglycaemia has traditionally been considered a complication of the treatment for type 1 diabetes, it has recently been recognised as a problem in people with type 2 diabetes particularly those on insulin therapy. In the ACCORD study, the risk of death was significantly increased in those with one or more episode of severe hypoglycaemia in both the strict and standard study treatment arms. As plasma glucose falls to below 4.0 mmol/L, a series of defence mechanisms occur, at an individualised glycaemic thresholds, to reverse hypoglycaemia including a rise in catecholamine levels. This may lead to hypokalaemia, prolonged QT interval, and cardiac arrhythmias. It may also lead to impaired cardiovascular autonomic function for up to 16 hours afterwards; increased inflammatory markers; platelet activation and promote vascular damage. As the majority of studies assessing the effects of hypoglycaemia on cardiovascular risk markers are conducted in people with type 1 diabetes and healthy controls, their findings may not necessarily be applicable to people with type 2 diabetes. In particular, the effects of hypoglycaemia on platelet function and thrombotic risk in people with type 2 diabetes require further clarification. In this study, we hypothesised that acute hypoglycaemia will result in platelet activation in people with type 2 diabetes to a higher degree than controls.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Hull, Det Forenede Kongerige, HU3 2RW
- Hull Royal Infirmary
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Healthy volunteers:
- Males or females
- On no medications except for the contraceptive pill and without medical illnesses in the last three months.
- Non-smokers
- 40 - 60 years of age.
T2DM subjects:
- Males or females
- Diagnosis of T2DM
- 40 - 60 years of age
- HbA1C: 6.5 - 9.5%
- Duration of diabetes 1 - 10 years
- Diabetes treated with diet, or tablets only.
Exclusion Criteria:
Healthy volunteers:
- Pregnancy
- Lack of contraception in women of child bearing age
- Chronic medical conditions
- Current smokers
- Evidence of ischaemia on ECG
- Drop attacks
- Alcohol or drug abuse
- Psychiatric illness
- Previous history of seizure
- Alcohol or drug abuse
Type 2 diabetes subjects:
- Pregnancy
- Current smokers
- Recurrent episodes of hypoglycaemia
- Treatment with anti-platelet or anti-coagulation therapy
- History of ischaemic heart disease, stroke or peripheral vascular disease
- Epilepsy
- Drop attacks
- Evidence of ischaemia on ECG
- Insulin treated T2DM
- History of microvascular disease (retinopathy, nephropathy or neuropathy).
- Alcohol or drug abuse
- Psychiatric illness
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Diagnostisk
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Controls
Weight-matched healthy controls.
Euglycaemic Hypoglycaemic insulin clamp.
Using hyperinsulinaemic clamps, blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour.
Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
|
Using insulin and glucose infusions (hyperinsulinaemic clamps), blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour.
Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
Andre navne:
|
Aktiv komparator: Type 2 diabetes
People with a known diagnosis of type 2 diabetes.
Euglycaemic Hypoglycaemic Insulin clamp.
Using hyperinsulinaemic clamps, blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour.
Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
|
Using insulin and glucose infusions (hyperinsulinaemic clamps), blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour.
Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
To examine the effect of hypoglycaemia on platelet surface expression of platelet activation markers P-selectin and fibrinogen binding.
Tidsramme: Up to 24 hours after euglycaemic hypoglycaemic clamp
|
Platelet surface expression of activation markers, P-selectin and fibrinogen binding, were measured in the resting state (unstimulated samples) and in response to stimulation with platelet agonist adenosine diphosphate, and platelet inhibitor prostacyclin. A change in platelet function from times 0 (baseline), to 2 hours (euglycaemia), 4 hours (hypoglycaemia) and 24 hours after the clamp studies was measured and compared between the two groups. |
Up to 24 hours after euglycaemic hypoglycaemic clamp
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
To measure changes in markers of inflammation (high sensitivity C-reactive protein) and endothelial function using EndoPat 2000
Tidsramme: Up to 24h after euglycaemic hypoglycaemic clamp
|
High sensitivity C-reactive protein was measured at baseline (time 0), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and 24 hours after clamp studies. Changes from baseline were compared between the groups. EndoPat was measured before the insulin clamp and 24 hours afterwards and changes were compared between the two groups. |
Up to 24h after euglycaemic hypoglycaemic clamp
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
To assess the effects of hypoglycaemia on participants scores on cognitive function tests
Tidsramme: Up to 24h after euglycaemic hypoglycaemic clamp
|
Three cognitive function tests (Tower of Hanoi; Dual Task test and The Digit symbol-coding) were measured at baseline (time 0), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and 24 hours after insulin clamp studies.
Changes from baseline in each of these tests in response to the insulin clamp were compared between the two groups.
|
Up to 24h after euglycaemic hypoglycaemic clamp
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Stephen L Atkin, PhD, Hull York Medical School
Publikationer og nyttige links
Generelle publikationer
- Moin ASM, Sathyapalan T, Atkin SL, Butler AE. The severity and duration of Hypoglycemia affect platelet-derived protein responses in Caucasians. Cardiovasc Diabetol. 2022 Oct 6;21(1):202. doi: 10.1186/s12933-022-01639-w.
- Moin ASM, Kahal H, Al-Qaissi A, Kumar N, Sathyapalan T, Atkin SL, Butler AE. Amyloid-related protein changes associated with dementia differ according to severity of hypoglycemia. BMJ Open Diabetes Res Care. 2021 Apr;9(1):e002211. doi: 10.1136/bmjdrc-2021-002211.
- Moin ASM, Nandakumar M, Kahal H, Sathyapalan T, Atkin SL, Butler AE. Heat Shock-Related Protein Responses and Inflammatory Protein Changes Are Associated with Mild Prolonged Hypoglycemia. Cells. 2021 Nov 10;10(11):3109. doi: 10.3390/cells10113109.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 11/YH/0161
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Type 2 diabetes mellitus
-
US Department of Veterans AffairsAmerican Diabetes AssociationAfsluttetType 2 diabetes mellitusForenede Stater
-
Dexa Medica GroupAfsluttetType-2 diabetes mellitusIndonesien
-
University Hospital Inselspital, BerneAfsluttetType 2 diabetes mellitusSchweiz
-
India Diabetes Research Foundation & Dr. A. Ramachandran...Afsluttet
-
AstraZenecaRekruttering
-
Daewoong Pharmaceutical Co. LTD.Ikke rekrutterer endnuT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRekrutteringType 2 diabetes mellitus (T2DM)Kina
-
Newsoara Biopharma Co., Ltd.RekrutteringT2DM (Type 2 Diabetes Mellitus)Kina
-
Shanghai Golden Leaf MedTec Co. LtdAktiv, ikke rekrutterendeType 2 diabetes mellitus (T2DM)Kina
-
SanofiAfsluttet
Kliniske forsøg med Insulin (Humulin S)
-
University of HullAfsluttetType 2-diabetes mellitus med hypoglykæmiDet Forenede Kongerige
-
Florida Atlantic UniversityAdvanced Diabetes Treatment CentersAfsluttetDiabetes | SårhelingForenede Stater
-
SanofiAfsluttetDiabetes mellitusForenede Stater
-
Halozyme TherapeuticsAfsluttetDiabetes mellitus, type 2Forenede Stater
-
Eli Lilly and CompanyAfsluttetDiabetes mellitus, type 2Forenede Stater
-
Florida Atlantic UniversityAdvanced Diabetes Treatment Centers; Global InfusionsTrukket tilbageHypoglykæmiForenede Stater
-
Halozyme TherapeuticsAfsluttet
-
Université NAZI BONIJuvenile Diabetes Research Foundation; International Society for Pediatric... og andre samarbejdspartnereRekrutteringType 1 diabetesBurkina Faso
-
Halozyme TherapeuticsAfsluttetType 1 diabetes mellitusForenede Stater
-
University of North Carolina, Chapel HillWakeMed Health and HospitalsAfsluttetGraviditet | Ikke-insulinafhængig diabetesForenede Stater